The company has launched the tablets in the strength of 0.1 mg in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc, Ajanta Pharma said in a BSE filing.
The product is a generic version of Concordia Pharmaceuticals Inc's Kapvay tablets, it added.
The tablets are a part of the growing portfolio of products that the company has developed for the US market, Ajanta Pharma said.
Clonidine Hydrochloride extended release tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD).
Till date, the drug maker has launched 16 products in the US market.
Shares of Ajanta Pharma today closed 0.54 per cent higher at Rs 1,343.35 per scrip on BSE today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app